Subacute Subclinical Brain Infarctions after Transcatheter Aortic Valve Implantation Negatively Impact Cognitive Function in Long-Term Follow-Up

Alexander Ghanem1,2*, Jonas Dörner3,4*, Leonie Schulze-Hagen2, Andreas Müller4, Marius Wilsing2, Jan-Malte Sinning2, Julian Lütkens4, Christian Frerker1, Karl-Heinz Kuck1, Ingo Gräff4, Hans Schild4, Nikos Werner4, Eberhard Grube4, Georg Nickenig2*

1 Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany, 2 Department of Cardiology, University Hospital Bonn, Germany, 3 Department of Radiology, University Hospital Cologne, Germany, 4 Department of Radiology, University Hospital Bonn, Germany, 5 Emergency Department, University Hospital Bonn, Bonn, Germany

☯ These authors contributed equally to this work.

* aghanem@web.de (AG); georg.nickenig@ukb.uni-bonn.de (GN)

Abstract

Aims
To date every post-procedural cerebrovascular embolic event (CVE) is dreaded for its potential to accelerate cognitive decline after transcatheter aortic valve implantation (TAVI). This study differentiates the impact of acute (procedural) and post-acute cerebrovascular embolic events (CVEs) on cognitive performance.

Methods
Magnetic resonance imaging (MRI) before, early and late after TAVI was performed to quantify embolic burden. Quantification of diffusion- and T1-weighted lesions, as well as white-matter and total brain volumes, as well as cognitive function testing (MMSE) were assessed in 28 patients with a medium follow-up period of 34 months.

Results
Procedural diffusion-weighted lesions were observed in 17 patients (61%), but demonstrated locoregional remnants only in a minority of patients in long-term follow-up (6.5%). Acute CVEs did not impact the trajectory of late silent brain infarctions (SBI), white-matter hyperintensities, and cerebral atrophy. Functionally, early CVEs did not affect cognitive function. In contrast, patients with “new” SBIs after TAVI had a trend to cognitive deterioration in long-term follow-up (“new”SBI: MMSE -1.4 / no “new”SBI: MMSE +1.5, p = 0.067). Interestingly, only a fraction of these “new” SBIs evolved from procedural CVEs (22%).
Conclusions

Aquired SBIs after TAVI, but not DW-CVE per se are associated with functional impairment long-term after TAVI. In the context of subacute thrombosis seen in TAVI prostheses, these findings set the stage for tailored stroke prevention and comprehensive surrogate endpoint definitions in neuroprotective trials.

Background

Transcatheter aortic valve implantation (TAVI) is a valid therapeutic option for the treatment of aortic valve stenosis in patients at high risk for surgery [1]. The benefits, however, are mitigated by the occurrence of (post-)procedural cerebrovascular embolic events (CVEs). The great majority of patients (63–84%) demonstrate clinically silent CVEs in diffusion-weighted magnetic resonance imaging (DW-MRI), disabling and non-disabling strokes are rare (1–3%) events [2–4]. The cumulated risk of CVEs remains elevated in the first post-procedural year, most conceivably associated with thrombogenicity of the device and the new-onset of atrial fibrillation [5, 6]. Since the incidence of CVEs in DW-MRI is widely utilized as a surrogate parameter of stroke risk, e.g. in neuroprotective approaches, and TAVI is more frequently utilized in younger, intermediate-risk patients, the contributions of silent microembolism to the functional and morphological cerebral outcome are of paramount importance.

The occurrence and accumulation of silent brain infarctions (SBIs) in T2-weighted MRI was shown to be correlated with cognitive decline in the large-scale Rotterdam-Scan-Study [7]. Knowing this, CVEs in DW-MRI after TAVI are dreaded for their potential adverse impact on cerebral morphology and consecutive impairment of cognitive performance. However, the functional impact of CVEs in DW-MRI after surgery with extracorporal circulation remains controversially discussed, with mixed results across studies [8, 9]. In the context of TAVI, the morphological proof of CVEs in DW-MRI has not been shown to be causally connected to functional outcomes. CVEs were neither associated with negative cognitive outcomes, nor with dependence in daily activities or mortality [10, 11]. These observations were recently flanked by a meta-analysis, which has shown that the risk of cognitive decline after cardiovascular procedures is low, despite the knowledge on the interventions’ high cerebral embolic burden [12]. In all, the functional impact and long-term prognosis of silent CVEs seen with DW-MRI is not elucidated yet.

Evidence of SBIs is not uncommon in the elderly and increasing with age [13]. Besides SBIs, adverse cerebral remodelling measured by repetitive MRI encompasses also the less specific entities of white-matter hyperintensities (WMH) and cerebral atrophy (CA) [14]. Large observational studies demonstrated the association of SBIs with both, subclinical heart failure, as well as impaired cognitive outcome in patients without overt cerebrovascular events [7, 15, 16]. It was further demonstrated, that WMH-burden, especially a significant increase over time, as well as significant atrophy of brain tissue are both associated with cognitive deterioration [17]. Early signs of adverse cerebral remodelling are correlated with increased long-term risk for stroke and death [18]. However, only a fraction of TAVI-related DW-CVEs resulted in SBIs in T2-weighted MRI after three months [2]. Hence, the dreaded causality of TAVI-related acute CVEs in DW-MRI and consecutive aggravation of adverse remodelling in long-term trajectories remains elusive.

We hypothesized, that in long-term observations specifically the acquisition of SBIs (and not any DW-CVEs per se) affects brain morphology and cognition. Hence, we investigated the
differential impact of early and later CVEs on functional and morphological outcome in a pro-
spective study with long-term follow-up of cognitive function assessment and cerebral imaging
with MRI.

Methods
All patients scheduled for TAVI between October 2009 and September 2010 were screened for
inclusion, aiming at a minimum follow-up period of 30 months. Indication for TAVI was in
concordance with the recent consensus statement [19]. Inclusion and exclusion criteria are
depicted in the methods supplement (S1 Methods). The study protocol was approved by the
local institutional review board and followed the Declaration of Helsinki guidelines. Written
informed consent was obtained from all patients.

Study design
Baseline examinations (BL) were performed within five days prior TAVI. After careful investi-
gation of medical history, the mortality risk was estimated by both, the logistic EuroSCORE
and the risk score of the Society of Thoracic Surgeons (Society of Thoracic Surgeons score:
mortality). Twelve-lead surface ECG, serological and hematological analyses, transthoracic
and transesophageal echocardiography, color-coded duplex sonography of the extracranial
carotid arteries, and coronary angiography were conducted. Clinical examinations according
to the National Institutes of Health Stroke Scale (NIHSS) were performed. Furthermore, the
repeatable mini-mental state exam for the assessment of general cognitive function (MMSE)
was conducted by a trained neuropsychological research fellow. The MMSE is a valid neuro-
psychological testing battery, which is suited for the assessment of cognition in elderly subjects.
We additionally assessed frailty, quality of life, instrumental activities of daily living, and mood
using the following validated scores and questionnaires: The Edmonton frail scale scores of ≤3
and >7 indicate a lower (odds ratio: 0.3) and excessive risk (odds ratio: 5.0) of having a com-
plication after surgery, respectively. The health-related short form allows the assessment of
mental and physical health–related status on a scale ranging from 0 to 100. The Lawton instru-
mental activities of daily living score displays function in daily activities, with higher values
reflecting better function; a value >52 has previously been used to determine independent life-
style. The geriatric depression score is a 30-item report, which displays patient mood on a
scale ranging from 0 to 30, with a value <10 reflecting lack of depressive symptoms. The
occurrence of systemic inflammatory response syndrome (SIRS) was defined as fulfilling ≥2
of the following 4 criteria: body temperature <36.0°C or >38.0°C, heart rate >90 bpm, respira-
atory rate >20 breaths/min, or PaCO₂ <32 mm Hg, leukocyte count >12 or <4 (10⁹/L) 1, 6,
24, 48, or 72 hours after TAVI. Preprocedural cerebral DW-MRI was performed within three
days prior TAVI. First postprocedural investigations (FU1) were performed within three days
after TAVI, second follow-up investigations (FU2) were performed after at least 30 months.

Cerebral magnetic resonance imaging
Cerebral MRI was performed using a 1.5-T whole body system (Philips Medical Systems, Best,
The Netherlands). The scanning protocol comprised transversal T1-weighted, transversal
T2-weighted, transversal Fluid Attenuated Inversion Recovery (FLAIR) as well as transversal
and coronal diffusion-weighted imaging, respectively. A single trained board-certified neuro-
radiologist who was unaware of the patients’ history of stroke and transient ischemic attack
scored and quantified lesions on the baseline and the two follow-up MRIs with respect to their
location and size. As described previously, we regarded the progressions of WMH >1.5%/year
and CA >1%/year as significant. Detailed imaging protocols and method of data analysis are presented in the methods supplement (S1 Methods).

Transcatheter aortic valve implantation

TAVI was performed in spontaneously breathing patients in deep sedation using midazolam, propofol, and fentanyl. Details are described in the methods supplement (S1 Methods). In a subset of patients, valvuloplasty, rapid ventricular pacing, and postdilatation were omitted at the discretion of the operator. This approach has been described recently and was abbreviated as direct TAVI.

Statistical analyses

Continuous variables are presented as mean±SD if normally distributed and as median (interquartile range) if not normally distributed. Categorical variables are given as frequencies and percentages and were compared by χ² statistics or Fisher exact test. Continuous variables were tested for differences by means of a 2-sided, unpaired Student t test for comparison between groups and with a 2-sided, paired Student t test for intragroup comparison. Nonparametric testing (Mann–Whitney test) was performed where indicated. A value of P<0.05 was considered statistically significant. Analyses were conducted with SPSS Statistics version 17.0.0 (22.0.0) (SPSS Inc, Chicago, IL).

Results

Patient baseline characteristics were comparable to previously published data (see Table 1). Twenty-eight patients were followed-up for a mean of 2.8 years (33.6 months). During the follow-up period, no clinically apparent cerebrovascular accident was observed. At baseline (BL) no patient had CVEs in DW-MRI. Ten patients (35.7%) had 14 SBIs (range 1–3 / patient). At FU1, 17 of 28 patients (60.7%) demonstrated 61 acute post-procedural CVEs in DW-MRI (range 1–14 / patient). At FU2, all patients were negative for DW-CVEs. Notably, 17 of 28 patients demonstrated 32 SBIs (60.7%, range 1–5 / patient), 12 of these patients had 18 "new" SBIs at FU2 (Fig 1).

Baseline characteristics were distributed equally with respect to procedural events (see Table 2). Also, none of the baseline characteristics was associated with the occurrence of "new" SBIs at FU2. In particular, patients with "new" SBIs have equally distributed procedural events in DW-MRI (see Table 3). Seven patients (25%) had their first-ever SBI during the follow-up period. Of those, two had a loco-regionally “matched”, procedural event. On the contrary, two patients had no corresponding post-procedural CVE in DW-MRI. So, the majority of "new" SBIs were not causally related to the procedure itself. Of 61 DW-lesions obtained in FU1, only a fraction (n = 4, 6.5%) had a visible residuum in T1- and T2-weighted MRI at FU2, whereas the majority (93.5%) was not demarkated. Of the 18 new SBIs at FU2, only 4 (22.2%) were off-springs and causally related to an early, procedural DW-positive event at FU1 derived from the procedure itself. For details see Fig 2, two representative MRI-datasets are displayed in Fig 3.

White-matter hyperintensities (WMH) were present in all patients (n = 28, 100%) at baseline. The mean WMH-burden at BL was 12.8 ±9.1 ml (Median: 13.5, interquartile range: 4.2–19.6), accounting for 0.1–2.8% of the total intracranial volume (mean 0.9 ± 0.7%). The mean WMH-burden at FU2 increased to 16.4 ±11.9 ml (Median: 15.3, interquartile range: 6.3–23.1, p < 0.001), accounting for 0.1–3.2% of the total intracranial volume (mean 1.2 ± 0.9%) and resulting in a mean increase of WMH-burden of 1.3 ml/year. Twenty-four of the 28 patients demonstrated an increase of WMH-volume exceeding 1.5%/a, indicating accelerated
## Table 1. Clinical baseline characteristics.

| Clinical Data @ BL |   |
|--------------------|---|
| **N**              | 28 |
| **Age, years ±SD** | 80 ±6 |
| **Male, n (%)**    | 14 (50) |
| **Body mass index, kg/m² ±SD** | 25.6 ±5.0 |
| **Log EuroSCORE, % ±SD** | 24.1 ±17.9 |
| **STS score: mortality, % ±SD** | 7.5 ±6.9 |
| **STS score: permanent stroke, % ±SD** | 3.0 ±1.8 |
| **Peak-to-peak gradient, mmHg ±SD** | 48 ±22 |
| **Ejection fraction, % ±SD** | 49 ±15 |
| **NYHA class ±SD** | 3 ±1 |
| **Minimental state examination score @ BL** | 26.6 ±2.8 |
| **Minimental state examination score @ FU2** | 26.7 ±3.6 |

### Comorbidities

|                |   |
|----------------|---|
| **Hypertension, n (%)** | 26 (93) |
| **Diabetes, n (%)** | 4 (14) |
| **Smoking, n (%)** | 6 (21) |
| **Dyslipidemia, n (%)** | 17 (61) |
| **Creatinine, mg/dl ±SD** | 1.2 ± 0.4 |
| **Glomerular fibrilation rate, ml/min ±SD** | 55 ± 9 |
| **Hemodialysis, n (%)** | 0 (0) |
| **Atrial fibrillation or flutter, n (%)** | 8 (29) |
| **CHADS₂-Score ±SD** | 2.5 ± 1.2 |
| **Prior stroke or TIA, n (%)** | 7 (25) |
| **PVD, n (%)** | 10 (36) |
| **Coronary artery disease, n (%)** | 14 (50) |
| **Prior myocardial infarction, n (%)** | 4 (14) |
| **Prior PCI, n (%)** | 8 (29) |
| **Prior CABG, n (%)** | 1 (4) |

### Procedural characteristics

|                |   |
|----------------|---|
| **Procedure time, min ±SD** | 98 ± 54 |
| **Direct TAVI without predilatation, n (%)** | 8 (29) |
| **Corevalve 23/26/29/31 mm, n** | 0/9/12/2 |
| **Edwards-Sapien 23/26 mm, n** | 2/1 |
| **Symetis 23 mm, n** | 2 |
| **Post-dilatation, n (%)** | 7 (25) |
| **Rapid pacing runs, n (%)** | 1.1 ± 1.0 |

### Post-procedural characteristics @ FU 1

|                |   |
|----------------|---|
| **SIRS, n (%)** | 8 (29) |
| **Minor bleeding, n (%)** | 10 (36) |
| **Major bleeding, n (%)** | 1 (4) |
| **Stroke, n (%)** | 0 (0) |
| **Evidence of embolic events in DW-MRI, n(%)** | 17 (61) |

### Medication @ FU 2

|                |   |
|----------------|---|
| **Acetylsalicylic acid, n (%)** | 21 (75) |
| **Clopidogrel hydrogen sulphate, n (%)** | 3 (11) |
| **Beta-blocker, n (%)** | 24 (86) |
| **Statin, n (%)** | 17 (61) |

(Continued)
WMH-formation. Patients with and without accelerated WMH-formation had no significant differences with respect to the occurrence of procedural CVEs at FU1, and baseline characteristics. The occurrence of new SBIs at FU2 was associated with a slight, but not significant increase of total WMH-volume ("new" SBIs: WMH-volume +18.3%/a; no "new" SBIs: WMH-volume + 12.1%/a; p = 0.28).

The mean total brain volume (TBV) at BL was 1183 +/-119 ml (Median: 1185, interquartile range: 1108–1255), the mean TBV at FU2 decreased to 1114 +/-112 ml (Median: 1092 ml, interquartile range: 1040–1199 ml). Eighteen of the 28 patients demonstrated a decrease of TBV exceeding 1%/a, indicating accelerated brain atrophy. Patients with and without accelerated brain atrophy had no significant differences with respect to the occurrence of DW-CVEs at FU1, and baseline characteristics. The occurrence of new SBIs at FU2 was not associated with a significant decrease of TBV ("new" SBIs: TBV –2.0%/a; no "new" SBIs: TBV– 2.5%/a; p = 0.59).

The mean MMSE scores of the entire cohort at baseline and FU2 demonstrated no significant difference and were 26.6 +/-2.9 and 26.7 +/-3.7, respectively (p = 0.88). Neither the occurrence of WMH-increase over time, nor the TBV-decrease at FU2, and distinctly not DW-CVEs at BL impacted MMSE-trajectory negatively. In contrast, the presence of "new" SBIs at FU2 negatively impacted MMSE-trajectories during follow-up ("new" SBI: MMSE -1.4 / no "new" SBI: MMSE +1.5, p = 0.067), indicating a negative functional effect of new SBIs, but not other imaging parameters on cognitive function (Fig 4).

### Table 1. (Continued)

| AT1 antagonist, n (%) | 9 (32) |
| ACE inhibitor, n (%) | 14 (50) |
| Diuretics, n (%) | 22 (79) |

doi:10.1371/journal.pone.0168852.t001

Fig 1. Morphological cerebral outcome after TAVI. The majority of patients (60.7%) had acute lesions in cerebral diffusion-weighted magnetic resonance imaging (DW-MRI) after TAVI. However, there was no association of these acute events (DW-CVEs) and the incidence of SBIs after long-term follow-up. Moreover, DW-CVEs neither aggravated the progression of white matter hyperintensities (> 1.5%/ year), nor the progression of cerebral atrophy (> 1%/ year). TAVI—Transcatheter aortic valve implantation, DW—diffusion-weighted, CVE—cerebrovascular event, MRI—magnetic resonance imaging, WMH—white matter hyperintensities, TBV—total brain volume, FLAIR—Fluid Attenuated Inversion Recovery.

doi:10.1371/journal.pone.0168852.g001
Table 2. Univariate analyses of clinical baseline characteristics dichotomized for the occurrence of a new procedural DWI event at follow-up 1.

| Clinical Data | DWI Lesion Present @ FU1 (n = 17) | DWI Lesion Absent @ FU1 (n = 11) | p-Value |
|---------------|-----------------------------------|----------------------------------|---------|
| Age, years ±SD| 81 ±6                             | 79 ±6                            | 0.55    |
| Male, n (%)   | 10 (59)                           | 4 (36)                           | 0.44    |
| Body mass index, kg/m² ±SD | 24.8 ±5.2            | 26.9 ±4.5                        | 0.27    |
| Log EuroSCORE, % ±SD  | 22.9 ±17.1                      | 25.8 ±19.8                       | 0.69    |
| STS score: mortality, % ±SD | 7.8 ±7.7                     | 7.0 ±5.7                         | 0.75    |
| STS score: permanent stroke, % ±SD | 2.7 ±0.8                  | 3.5 ±2.7                         | 0.24    |
| Peak-to-peak gradient, mmHg ±SD | 46 ±21                       | 52 ±25                           | 0.45    |
| Ejection fraction, % ±SD  | 51 ±15                           | 46 ±15                           | 0.40    |
| NYHA class ±SD | 3 ±1                           | 3 ±0                             | 0.39    |
| Minimental state examination score BL | 26.1 ±3.2                  | 27.3 ±3.2                        | 0.33    |
| Minimental state examination score FU2 | 26.2 ±4.4                  | 27.5 ±2.2                        | 0.40    |
| Hypertension, n (%) | 17 (100)                      | 9 (82)                           | 0.15    |
| Diabetes, n (%) | 2 (12)                         | 2 (18)                           | 1.00    |
| Smoking, n (%)  | 4 (24)                          | 2 (18)                           | 1.00    |
| Dyslipidemia, n (%) | 10 (59)                      | 7 (64)                           | 1.00    |
| Creatinine, mg/dl ±SD | 1.1 ±0.2                    | 1.3 ±0.6                         | 0.35    |
| Glomerular filtration rate, ml/min ±SD | 53.8 ±8.9                 | 55.9 ±9.8                        | 0.19    |
| Hemodialysis, n (%) | 0 (0)                         | 0 (0)                            | -       |
| Atrial fibrillation or flutter, n (%) | 5 (29)                      | 3 (27)                           | 1.00    |
| CHADS₂-Score ±SD | 2 ±1                           | 3 ±1                             | 0.18    |
| Prior stroke or TIA, n (%) | 1 (6)                         | 6 (55)                           | 0.01    |
| Coronary artery disease, n (%) | 10 (59)                     | 4 (36)                           | 0.44    |
| Prior myocardial infarction, n (%) | 2 (12)                        | 2 (18)                           | 1.00    |
| Prior PCI, n (%)  | 6 (35)                          | 2 (18)                           | 0.42    |
| Prior CABG, n (%) | 1 (6)                         | 0 (0)                            | 1.00    |
| Procedure time, min ±SD | 109 ±66                     | 80 ±20                           | 0.17    |
| Direct TAVI without predilatation, n (%) | 12 (71)                    | 8 (73)                           | 1.00    |
| Corevalve 23/26/29/31 mm, n | 0/5/7/1                      | 0/4/5/1                          | -1/0/1/1.0 |
| Edwards-Sapien 23/26 mm, n | 1/1                          | 1/0                              | 1.0/1.0 |
| Symetis 23 mm, n | 2                            | 0                                | 0.50    |
| Post-dilatation, n (%) | 3 (18)                        | 4 (36)                           | 0.38    |
| Rapid pacing runs, n (%)  | 1.2 ±1.2                      | 0.8 ±0.6                         | 0.86    |
| SIRS, n (%)       | 5 (29)                          | 3 (27)                           | 1.00    |
| Minor bleeding, n (%) | 6 (35)                        | 4 (36)                           | 1.00    |
| Major bleeding, n (%) | 1 (6)                         | 0 (0)                            | 1.00    |
| Stroke, n (%)     | 0 (0)                           | 0 (0)                            | -       |
| Acetylsalicylic acid, n (%) | 12 (71)                     | 9 (82)                           | 0.67    |
| Clopidogrel hydrogen sulphate, n (%) | 3 (18)                      | 0 (0)                            | 0.26    |
| Beta-blocker, n (%) | 15 (88)                        | 9 (82)                           | 1.00    |
| Statin, n (%)     | 10 (59)                         | 7 (64)                           | 1.00    |
| AT1 antagonist, n (%) | 5 (29)                        | 4 (36)                           | 1.00    |
| ACE inhibitor, n (%) | 8 (47)                        | 6 (55)                           | 1.00    |
| Diuretics, n (%)  | 14 (82)                         | 8 (73)                           | 0.65    |

doi:10.1371/journal.pone.0168852.t002
Table 3. Univariate analyses of clinical baseline characteristics dichotomized for the occurrence of new SBIs at follow-up 2.

| Clinical Data | “New” SBI present @FU2 (n = 12) | “New” SBI absent @FU2 (n = 16) | p-Value |
|---------------|---------------------------------|-------------------------------|---------|
| Age, years ±SD| 81 ±6                           | 80 ±6                         | 0.54    |
| Male, n (%)   | 7 (58)                          | 7 (44)                        | 0.70    |
| Body mass index, kg/m² ±SD | 25.3 ±4.5                  | 25.9 ±5.5                     | 0.76    |
| Log EuroSCORE, % ±SD | 23.6 ±18.6                | 24.4 ±18.0                    | 0.91    |
| STS score: mortality, % ±SD | 7.1 ±5.4                   | 7.8 ±8.0                      | 0.81    |
| STS score: permanent stroke, % ±SD | 2.5 ±1.0                   | 3.4 ±2.2                      | 0.23    |
| Peak-to-peak gradient, mmHg ±SD | 40.3 ±22.8                 | 54.4 ±20.7                    | 0.10    |
| Ejection fraction, % ±SD | 50.0 ±15.2                 | 48.4 ±15.5                    | 0.78    |
| NYHA class ±SD | 2.9 ±0.3                    | 2.9 ±0.7                      | 0.92    |
| Minimental state examination score BL | 27.1 ±2.7                | 26.2 ±3.0                     | 0.43    |
| Minimental state examination score FU 2 | 25.7 ±0.3                | 27.7 ±1.9                     | 0.17    |

**Comorbidities**

| Hypertension, n (%) | 11 (92) | 15 (94) | 1.00 |
| Diabetes, n (%)     | 1 (8)   | 3 (19)  | 0.61 |
| Smoking, n (%)       | 2 (17)  | 4 (25)  | 0.67 |
| Dyslipidemia, n (%)  | 8 (67)  | 9 (56)  | 0.71 |
| Creatinine, mg/dl ±SD | 1.1 ±0.2    | 1.2 ±0.6      | 0.49 |
| Glomerular filtration rate, ml/min ±SD | 59.7 ±8.7  | 56.5 ±15.1    | 0.52 |
| Hemodialysis, n (%)  | 0 (0)   | 0 (0)   | -     |
| Atrial fibrillation or flutter, n (%) | 3 (25)   | 5 (31)  | 1.00 |
| CHADS²-Score ±SD     | 2.3 ±0.8 | 2.8 ±1.4 | 0.27 |
| Prior stroke or TIA, n (%) | 1 (8)   | 6 (38)  | 0.18 |
| PVD, n (%)            | 3 (25)  | 7 (44)  | 0.43 |
| Coronary artery disease, n (%) | 5 (42)  | 9 (56)  | 0.70 |
| Prior myocardial infarction, n (%) | 3 (25)  | 1 (6)   | 0.29 |
| Prior PCI, n (%)      | 2 (17)  | 6 (38)  | 0.40 |
| Prior CABG, n (%)     | 1 (8)   | 0 (0)   | 0.43 |

**Procedural characteristics**

| Procedure time, min ±SD | 79.1 ±33.2 | 111.6 ±63.1 | 0.12 |
| Direct TAVI without predilatation, n (%) | 3 (25) | 5 (31) | 1.00 |
| Corevalve 23/26/29/31 mm, n | 0/0/4/5/2 | 0/5/7/0 | -/1.00/1.00/0.18 |
| Edwards-Sapien 23/26 mm, n | 0/0 | 2/1 | 0.49/1.0 |
| Symetis 23 mm, n | 1 | 1 | 1.00 |
| Post-dilatation, n (%) | 1 (8) | 6 (38) | 0.18 |
| Rapid pacing runs, n (%) | 0.9 ±0.7 | 1.2 ±1.2 | 0.50 |

**Post-procedural characteristics**

| SIRS, n (%) | 3 (25) | 5 (31) | 1.00 |
| Minor bleeding, n (%) | 2 (17) | 8 (50) | 0.11 |
| Major bleeding, n (%) | 0 (0) | 1 (6) | 1.00 |
| Stroke, n (%) | 0 (0) | 0 (0) | - |
| Evidence of embolic events in DW-MRI, n(%) | 8 (67) | 9 (56) | 0.71 |

**Medication @FU2**

| Acetylsalicylic acid, n (%) | 8 (67) | 13 (81) | 0.42 |
| Clopidogrel hydrogen sulphate, n (%) | 1 (8) | 2 (13) | 1.00 |
| Beta-blocker, n (%) | 10 (83) | 14 (88) | 1.00 |
| Statin, n (%) | 6 (50) | 11 (69) | 0.44 |
| AT1 antagonist, n (%) | 2 (17) | 7 (44) | 0.22 |

(Continued)
Discussion

This is the first report on morphological and functional long-term outcome of CVEs after TAVI. In spite of the raised concerns on the high incidence of procedural, silent cerebral embolism, this study adds several new insights: Firstly, only a fraction of the cumulative cerebral embolic burden throughout the first three years after TAVI is related to the procedure itself. More than 95% of the new SBIs in follow-up were not related to the TAVI-procedure itself. Secondly, DW-CVEs had no impact on late adverse cerebral morphological outcome. The incidences of SBIs and brain atrophy, as well as the trajectories of WMH were independent of the occurrence of procedural DW-CVEs. Ultimately, we observed the trend, that new SBIs, but not DW-CVEs, negatively impacted cognitive outcome. Hence, the dreaded long-term effects of DW-CVEs on brain morphology and function could not be objectified after a median of three years of follow-up.

Longitudinal imaging studies on the fate of procedural embolism are of particular interest, since the dreaded risk for future stroke and cognitive deterioration is limited to the presence of...
SBIs. In the large-scale Rotterdam Scan Study (> 1000 normal elderly, mean age 71, followed over 3.6 years), the presence of SBIs on the baseline MRI was associated with worse performance on neuropsychological tests and a steeper decline in global cognitive function. Interestingly, when participants with SBIs at baseline were subdivided into those with and those without additional infarcts at follow-up, the decline in cognitive function was restricted to those with additional silent infarcts [7]. Recent meta-analyses demonstrated that SBIs of small volume (< 3mm) were independent predictors of later stroke and mortality [18]. The protocol allowed us to differentiate the effects of the short, but intense embolic “rainstorm” during the procedure from the long-lasting, continuous embolic “drizzle” based on the acquired risk factors (NOAF, valve thrombosis). Longitudinal study protocols utilize cerebral MRI as a “biological event recorder” integrating and cumulating all procedural and post-procedural cerebral events.
throughout the follow-up period. Despite the dreaded impact of procedural embolism, only a small fraction (6.5%) of TAVI-induced DW-CVEs resulted in SBIs in long-term follow-up. This finding objectifies the very limited part of the peri-procedural embolic burden on the total structural cerebral remodelling during follow-up. We observed that > 85% of the acquired SBIs after TAVI were not related to the embolism during the procedure itself. Hence, in future studies longitudinal imaging protocols could take post-embolic cerebral remodeling into account. As in experimental research, early DW- and follow-up T2-weighted MRI might indicate the area at risk and the infarct scar, respectively.

With advancing age, WMH-burden increases [14], and total brain volume decreases (cerebral atrophy). The extent of volume changes has been associated with declining scores in the modified MMSE and the Digit Symbol Substitution Test, as well as with incident MCI, dementia, and death [20, 21]. More recent studies demonstrated that progression of WMH is a better predictor of persistent cognitive impairment than baseline WMH-burden alone [17]. The group of Silbert et al. have further shown that in a cohort of octogenarians greater WMH progression rate is associated with increased rate of decline on gait and memory function in cognitively intact elderly [17]. WMH acceleration may directly result in cognitive decline years later. Interestingly, the acceleration in WMH volume increase occurred 3.7 years before the onset of cognitive deterioration [17]. Hence, WMH-Progression was able to predict cognitive impairment in a very early phase. Based on the cut-off values in neurodegenerative disease, a loss of more than 1% / year total brain volume was set as significant for brain atrophy. In a large-scale observational study, total brain volume loss was significantly associated with cognitive impairment. Erten-Lyons and colleagues suggest that there may be other factors contributing to brain atrophy, e.g. cardiovascular risk factors [22]. We therefore utilized these two dynamic, intraindividual parameters of cerebral remodelling to sensitively investigate the dreaded adverse impact of DW-CVEs. Despite the advanced age and comorbid conditions of our study population, DW-CVEs had neither impact on the course of WMH-burden and cerebral atrophy after TAVI in our cohort.

In a functional follow-up study, the occurrence of DW-CVEs after TAVI did not impact cognitive trajectories for up to two years [10]. Further, a recent meta-analysis objectified the low risk of cognitive impairment after cardiovascular interventions [12]. This is of particular
interest in spite of the known high emboligeneic burden of these procedures with a DW-CVE-risk of up to 84%. However, DW-CVEs were not associated with worse outcomes with respect to self-sufficiency in daily activities, quality of life, cognitive performance and trajectories, as well as mortality after TAVI [9, 11]. Here, new SBIs but not DW-CVEs negatively impacted functional outcome. Although statistically the results missed the level of significance, the patients with SBIs at FU2 decreased in MMSE score by 1.4 points, whereas patients without new SBIs improved by 1.5 points. These results are not only reasonable since only 1 in 14 DW-lesions resulted in local adverse remodelling and SBI formation. Also, the remainder (77.8%) of embolic events cumulated throughout the follow-up period and were not local remnants of the acute DW-CVEs. Beside NOAF, valvular thrombosis was recently published as a potential mechanism of subacute stroke after TAVI [6]. Pache and colleagues described early hypo-attenuated leaflet thickening, which was reversed by oral anticoagulation. This transient thrombosis of valvular leaflets is a mechanism explaining subacute events and could be the reason for the observed rate of „new”SBIs. Hence, thrombus formation might further explain the high proportion of patients experiencing their „first”SBI after TAVI. As additional neuroprotective approach, oral anticoagulants are currently investigated for their value in prevention of subacute stroke after TAVI.

Limitations

This is a monocentric observation of a small patient cohort, however the first to provide long-term imaging follow-up. Mini-mental state exam is a coarse test which has its known limitations. But the MMSE is a valid tool, which can be set into context with a plethora of published datasets. Cerebral imaging was mostly performed with 1.5, and not 3 Tesla. Not all lesions attributed to CVD-BI on MRI are in fact caused by vascular injury. However, due to the lack of long-term imaging investigations, currently we are not able to specifically differentiate embolic from degenerative disease. Although it is known, that the embolic risk is highest during the first month after TAVI, the exact timepoint of post-procedural SBIs between FU1 and FU2 remains unclear and needs to be further elucidated in future trials.

Conclusions

In all, this pilot study tones down the dreaded impact of silent, procedural events seen in DW-MRI on functional and morphological long-term outcome in a high-risk population. Functional long-term prognosis seems to be determined by the accumulation of SBIs and should be considered in future studies of neuroprotective approaches.

Supporting Information

S1 Methods. Supplementary Methods. Transfemoral aortic valve implantation Cranial MRI and imaging analysis.

Author Contributions

Conceived and designed the experiments: AG JD LSH AM GN.

Performed the experiments: AG JD LSH AM MW JMS CF KK JL HS NW EG GN.

Analyzed the data: AG JD MW.
Contributed reagents/materials/analysis tools: AG JD LSH AM MW JMS CF KK IG JL HS NW EG GN.

Wrote the paper: AG JD LSH AM MW JMS CF KK IG JL HS NW EG GN.

Revised the manuscript: AG JD LSH AM MW JMS CF KK IG JL HS NW EG GN.

References

1. Leon MB, Smith CR, Mack M, Miller DC, Svensson LG, et al. (2010) PARTNER Trial Investigators. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med; 363:1597–1607. doi: 10.1056/NEJMoa1008232 PMID: 20961243

2. Ghanem A, Müller A, Nähle CP, Kocurek J, Werner N, Hammerstingl C, et al. (2010) Risk and Fate of Cerebral Embolism After Transfemoral Aortic Valve Implantation: A Prospective Pilot Study With Diffusion-Weighted Magnetic Resonance Imaging. J Am Coll Cardiol; 55:1427–1432. doi: 10.1016/j.jacc.2009.12.026 PMID: 20188503

3. Kahler P, Knipp SC, Schlamann M, Al-Rashid F, Weber M, et al. (2010) Silent and Apparent Cerebral Ischemia After Percutaneous Transfemoral Aortic Valve Implantation: A Diffusion-Weighted Magnetic Resonance Imaging Study. Circulation; 121:870–878. doi: 10.1161/CIRCULATIONAHA.109.855866 PMID: 20177005

4. Kahler P, Al-Rashid F, Döttger P, Moit K, Pflicht B, Wendt D, et al. (2012) Cerebral Embolization During Transcatheter Aortic Valve Implantation: A Transcranial Doppler Study. Circulation; 126:1245–1255. doi: 10.1161/CIRCULATIONAHA.112.092544 PMID: 22899774

5. Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis RJ, Dager AE, et al. (2012) Timing, Predictive Factors and Prognostic Value of Cerebrovascular Events in a Large Cohort of Patients Undergoing Transcatheter Aortic Valve Implantation. Circulation; 126:3041–3053. doi: 10.1161/CIRCULATIONAHA.112.110981 PMID: 23149669

6. Pache G, Schoechlin S, Blanke P, Dorfs S, Jander N, Arapalli CD, et al. (2016) Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J; 37:2263–2271. doi: 10.1093/eurheartj/ehv526 PMID: 26446193

7. Vermeer SE, Prins ND, Heijer T den, Hofman A, Koudstaal PJ, Breteler MMB. (2003) Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline. N Engl J Med; 348:1215–1222. doi: 10.1056/NEJMoa022066 PMID: 12660385

8. Knipp SC, Matatko N, Schlamann M, Wilhelm H, Thielmann M, Forsting M, et al. (2005) Small ischemic brain lesions after cardiac valve replacement detected by diffusion-weighted magnetic resonance imaging: relation to neurocognitive function. Eur J Cardiothorac Surg; 28:88–96. doi: 10.1016/j.ejcts.2005.02.043 PMID: 15922616

9. Kruis RWJ, Vlasveld FAE, Van Dijk D. (2010) The (un)importance of cerebral microemboli. Semin Cardiothorac Vasc Anesth; 14:111–118. doi: 10.1177/1089253210370903 PMID: 20478951

10. Ghanem A, Kocurek J, Sinning JM, Wagner M, Becker BV, et al. (2013) Prognostic value of cerebral injury following transfemoral aortic valve implantation. EuroIntervention; 8:1296–1306. doi: 10.4244/EIJV8I11A198 PMID: 23538093

11. DeCarli C, Massaro J, Harvey D, Tullberg M, Au R, et al. (2005) Measures of brain morphology and infarction in the Framingham heart study: establishing what is normal. Neurobiol Aging; 26:491–510. doi: 10.1016/j.neurobiolaging.2004.05.004 PMID: 15653178

12. Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, et al. (2008) Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J; 29:2125–2132. doi: 10.1093/eurheartj/ehn341 PMID: 18667399
16. Russo C, Jin Z, Homma S, Elkind MS, Rundek T, Yoshita M, et al. (2013) Subclinical left ventricular dysfunction and silent cerebrovascular disease: the Cardiovascular Abnormalities and Brain Lesions (CABL) study. Circulation; 128:1105–1111. doi: 10.1161/CIRCULATIONAHA.113.001984 PMID: 23902759

17. Silbert LC, Howieson DB, Dodge H, Kaye JA. (2009) Cognitive impairment risk—White matter hyperintensity progression matters. Neurology; 73:120–125. doi: 10.1212/WNL.0b013e3181ad53fd PMID: 19597134

18. Windham BG, Deere B, Griswold ME, Wang W, Bezerra DC, Shibata D, et al. (2015) Small Brain Lesions and Incident Stroke and Mortality: A Cohort Study. Ann Intern Med; 163:22–31. doi: 10.7326/ M14-2057 PMID: 26148278

19. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, et al. (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol; 60:1438–1454. doi: 10.1016/j.jacc.2012.09.001 PMID: 23036636

20. Debette S, Markus HS. (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ; 341:c3666. doi: 10.1136/bmj.c3666 PMID: 20660506

21. Longstreth WT Jr., Arnold AM, Beauchamp NJ Jr, Manolio TA, Leftkowitz D, Jungreis C, et al. (2005) Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke; 36:56–61. doi: 10.1161/01.STR.0000149625.99732.68 PMID: 15589873

22. Erten-Lyons D, Dodge HH, Woltjer R, Silbert LC, Howieson DB, Kramer P, et al. (2013) Neuropathologic basis of age-associated brain atrophy. JAMA Neurol; 70:616–622. doi: 10.1001/jamaneurol.2013.1957 PMID: 23552888